Literature DB >> 15224502

Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.

S Yamagishi1, M Takeuchi, Y Inagaki, K Nakamura, T Imaizumi.   

Abstract

Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic derangements. In this review, we discuss the molecular mechanisms of diabetic retinopathy and nephropathy, especially focusing on advanced glycation end products (AGEs) and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in diseases, including diabetic microangiopathy, will be discussed in the next review article.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15224502

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  38 in total

Review 1.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.

Authors:  Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

2.  MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.

Authors:  Yuhki Sakuraoka; Tokihiko Sawada; Toshie Okada; Takayuki Shiraki; Yoshikazu Miura; Katsuya Hiraishi; Tatsushi Ohsawa; Masakazu Adachi; Jun-ichi Takino; Masayoshi Takeuchi; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

Review 3.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

4.  Actions of β-amyloid protein on human neurons are expressed through the amylin receptor.

Authors:  Jack H Jhamandas; Zongming Li; David Westaway; Jing Yang; Simran Jassar; David MacTavish
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

Review 5.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

6.  Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

Authors:  S Y Tang; M R Allen; R Phipps; D B Burr; D Vashishth
Journal:  Osteoporos Int       Date:  2008-10-11       Impact factor: 4.507

7.  Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Sho-Ichi Yamagishi
Journal:  J Ophthalmol       Date:  2010-06-22       Impact factor: 1.909

8.  Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis.

Authors:  Kikuo Isoda; Eduardo Folco; M Reza Marwali; Fumitaka Ohsuzu; Peter Libby
Journal:  Atherosclerosis       Date:  2007-12-27       Impact factor: 5.162

9.  Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats.

Authors:  Wei-Wei Zhu; Xue-Ping Liu; Nan Wu; Ting-Ting Zhao; Yong Zhao; Jie Zhang; Jian-Hua Shao
Journal:  Mol Cell Biochem       Date:  2007-05-09       Impact factor: 3.396

10.  Structural mechanism of ring-opening reaction of glucose by human serum albumin.

Authors:  Yu Wang; Haiyang Yu; Xiaoli Shi; Zhipu Luo; Donghai Lin; Mingdong Huang
Journal:  J Biol Chem       Date:  2013-04-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.